Accéder au contenu
Merck

Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents.

International clinical psychopharmacology (1996-09-01)
B Spivak, N Gonen, R Mester, E Averbuch, S Adlersberg, A Weizman
RÉSUMÉ

Neuroleptic malignant syndrome (NMS) is a severe side-effect of neuroleptic treatment. It is usually related to hypodopaminergic activity. A young schizophrenic patient who developed a typical episode of NMS during abrupt withdrawal of long-acting neuroleptic combined with anticholinergic treatment is described. NMS appeared following combined neuroleptic/ anticholinergic withdrawal and responded to procyclidine administration. The appearance of NMS after discontinuation of antidopaminergic treatment seems to be in conflict with the hypodopaminergic theory of this adverse effect. It is suggested that simultaneous withdrawal of both anticholinergic and neuroleptic medications, mainly long-acting neuroleptics, seems to be a risk factor for NMS.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Penfluridol, ≥97% (HPLC), powder